A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.

Phase 1 Completed 14 enrolled University of Oxford

Non-randomizedSingle-groupOpen-labelPrevention

Summary

This study is to assesss the safety and immunogenicity of vaccine based on Modified Vaccinia Ankara (MVA) expressing the 85A antigen (from Mycobacterium. tuberculosis). This vaccine is delivered intrdermally by a needle injection in healthy volunteers.

Timeline

Start: 2002-09
Primary completion: —
Completion: 2003-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MVA85A	Vaccine	5e+07 unknown	Other

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.

Summary

Timeline

Drugs

Indications